A Phase 1, Open-Label Study to Evaluate the Pharmacodynamics, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects

Trial Profile

A Phase 1, Open-Label Study to Evaluate the Pharmacodynamics, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs GMI 1271 (Primary) ; Filgrastim
  • Indications Stem cell mobilisation
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 30 Jun 2016 Planned number of patients changed from 42 to 54.
    • 30 Jun 2016 Status changed from active, no longer recruiting to recruiting.
    • 08 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top